Home

Articles from Sequana Medical NV

Press release: Transparency Notification from Shareholders
Transparency Notification from Shareholders
By Sequana Medical NV · Via GlobeNewswire · April 25, 2025
Press release: Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 22 May 2025
Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 22 May 2025
By Sequana Medical NV · Via GlobeNewswire · April 22, 2025
Press release: CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases
CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases
By Sequana Medical NV · Via GlobeNewswire · April 14, 2025
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT
By Sequana Medical NV · Via GlobeNewswire · April 8, 2025
Press release: Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025
Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025
By Sequana Medical NV · Via GlobeNewswire · March 27, 2025
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
By Sequana Medical NV · Via GlobeNewswire · March 20, 2025
Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
Sequana Medical announces 2024 Full Year Results and 2025 Outlook
By Sequana Medical NV · Via GlobeNewswire · March 18, 2025
Press Release: Transparency Notification from Shareholders
Transparency Notification from Shareholders
By Sequana Medical NV · Via GlobeNewswire · February 10, 2025
Transparency Notifications from Shareholders
Transparency Notifications from Shareholders
By Sequana Medical NV · Via GlobeNewswire · February 3, 2025
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT
By Sequana Medical NV · Via GlobeNewswire · January 24, 2025
Press release: Transparency Notification from Shareholders
Transparency Notification from Shareholders
By Sequana Medical NV · Via GlobeNewswire · January 13, 2025
Press release: Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
By Sequana Medical NV · Via GlobeNewswire · January 7, 2025
Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
By Sequana Medical NV · Via GlobeNewswire · January 6, 2025
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
By Sequana Medical NV · Via GlobeNewswire · December 23, 2024
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
By Sequana Medical NV · Via GlobeNewswire · November 18, 2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
By Sequana Medical NV · Via GlobeNewswire · June 6, 2024
Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®
PRESS RELEASE: REGULATED INFORMATION – INSIDE INFORMATION 22 MAY 2024, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · May 22, 2024
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION3 April 2024, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · April 3, 2024
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
By Sequana Medical NV · Via GlobeNewswire · April 3, 2024
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET
By Sequana Medical NV · Via GlobeNewswire · March 28, 2024
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
By Sequana Medical NV · Via GlobeNewswire · March 26, 2024
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
By Sequana Medical NV · Via GlobeNewswire · March 25, 2024
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024
By Sequana Medical NV · Via GlobeNewswire · February 28, 2024
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · January 29, 2024
Transparency Notifications from Shareholders
By Sequana Medical NV · Via GlobeNewswire · January 24, 2024
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · January 23, 2024
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION
By Sequana Medical NV · Via GlobeNewswire · January 15, 2024
Sequana Medical granted US CPT® III reimbursement codes for alfapump® system
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · January 3, 2024
Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
By Sequana Medical NV · Via GlobeNewswire · December 28, 2023
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
 
By Sequana Medical NV · Via GlobeNewswire · November 29, 2023
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION10 November 2023, 06:00 pm CET
By Sequana Medical NV · Via GlobeNewswire · November 10, 2023
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · October 19, 2023
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · October 18, 2023
Sequana Medical announces H1 2023 results and provides business update
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · September 14, 2023
Sequana Medical Notice of 2023 Half-year Results and Business Update
By Sequana Medical NV · Via GlobeNewswire · September 6, 2023
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · July 10, 2023
1,000th alfapump® implant completed
 
By Sequana Medical NV · Via GlobeNewswire · July 6, 2023
Sequana Medical announces results of Special General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · June 26, 2023
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION21 June 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · June 21, 2023
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · June 19, 2023
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
By Sequana Medical NV · Via GlobeNewswire · June 16, 2023
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
PRESS RELEASEREGULATED INFORMATION26 May 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · May 26, 2023
Sequana Medical announces results of Annual General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION25 May 2023, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · May 25, 2023
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION
By Sequana Medical NV · Via GlobeNewswire · May 15, 2023
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASEREGULATED INFORMATION10 May 2023, 06:00 p.m. CEST
By Sequana Medical NV · Via GlobeNewswire · May 10, 2023
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · May 2, 2023
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASEREGULATED INFORMATION27 April 2023, 07:00 p.m. CEST
By Sequana Medical NV · Via GlobeNewswire · April 27, 2023
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · April 3, 2023
Sequana Medical announces additional patents for DSR® in China and the United States
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · March 22, 2023
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · March 1, 2023
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION10 February 2023, 18:00 CET
By Sequana Medical NV · Via GlobeNewswire · February 10, 2023
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · February 9, 2023
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · February 9, 2023
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 8, 2023
Sequana Medical Notice of 2022 Full Year Results and Business Update
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 2, 2023
Sequana Medical announces grant of additional DSR® patent in United States
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 1, 2023
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
PRESS RELEASEREGULATED INFORMATION11 January 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · January 11, 2023
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION15 November 2022, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · November 15, 2022
Sequana Medical to present at Jefferies London Healthcare Conference
By Sequana Medical NV · Via GlobeNewswire · November 8, 2022
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION25 October 2022, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · October 25, 2022
Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®
By Sequana Medical NV · Via GlobeNewswire · October 21, 2022